These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Seidensticker R; Seidensticker M; Damm R; Mohnike K; Schütte K; Malfertheiner P; Van Buskirk M; Pech M; Amthauer H; Ricke J Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1109-18. PubMed ID: 22037709 [TBL] [Abstract][Full Text] [Related]
3. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Kennedy AS; McNeillie P; Dezarn WA; Nutting C; Sangro B; Wertman D; Garafalo M; Liu D; Coldwell D; Savin M; Jakobs T; Rose S; Warner R; Carter D; Sapareto S; Nag S; Gulec S; Calkins A; Gates VL; Salem R Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1494-500. PubMed ID: 19157721 [TBL] [Abstract][Full Text] [Related]
8. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. Abdelmaksoud MH; Louie JD; Hwang GL; Kothary N; Minor DR; Sze DY J Vasc Interv Radiol; 2012 Mar; 23(3):323-30.e1. PubMed ID: 22277275 [TBL] [Abstract][Full Text] [Related]
9. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059 [TBL] [Abstract][Full Text] [Related]
10. Changes in normal liver and spleen volume after radioembolization with (90)Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. Paprottka PM; Schmidt GP; Trumm CG; Hoffmann RT; Reiser MF; Jakobs TF Cardiovasc Intervent Radiol; 2011 Oct; 34(5):964-72. PubMed ID: 21748452 [TBL] [Abstract][Full Text] [Related]
11. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary? McCann JW; Larkin AM; Martino LJ; Eschelman DJ; Gonsalves CF; Brown DB J Vasc Interv Radiol; 2012 May; 23(5):661-7. PubMed ID: 22440592 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S; J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371 [TBL] [Abstract][Full Text] [Related]
13. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors. Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V Oncology; 2014; 86(1):24-32. PubMed ID: 24401529 [TBL] [Abstract][Full Text] [Related]
14. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hilgard P; Hamami M; Fouly AE; Scherag A; Müller S; Ertle J; Heusner T; Cicinnati VR; Paul A; Bockisch A; Gerken G; Antoch G Hepatology; 2010 Nov; 52(5):1741-9. PubMed ID: 21038413 [TBL] [Abstract][Full Text] [Related]
15. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. Young JY; Rhee TK; Atassi B; Gates VL; Kulik L; Mulcahy MF; Larson AC; Ryu RK; Sato KT; Lewandowski RJ; Omary RA; Salem R J Vasc Interv Radiol; 2007 Nov; 18(11):1375-82. PubMed ID: 18003987 [TBL] [Abstract][Full Text] [Related]
16. Hepatic yttrium-90 radioembolization for metastatic melanoma: a single-center experience. Memon K; Kuzel TM; Vouche M; Atassi R; Lewandowski RJ; Salem R Melanoma Res; 2014 Jun; 24(3):244-51. PubMed ID: 24638152 [TBL] [Abstract][Full Text] [Related]
17. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. Iñarrairaegui M; Thurston KG; Bilbao JI; D'Avola D; Rodriguez M; Arbizu J; Martinez-Cuesta A; Sangro B J Vasc Interv Radiol; 2010 Aug; 21(8):1205-12. PubMed ID: 20598574 [TBL] [Abstract][Full Text] [Related]
18. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Lam MGEH; Banerjee S; Louie JD; Abdelmaksoud MHK; Iagaru AH; Ennen RE; Sze DY Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1536-1547. PubMed ID: 23435742 [TBL] [Abstract][Full Text] [Related]
19. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. Su YK; Mackey RV; Riaz A; Gates VL; Benson AB; Miller FH; Yaghmai V; Gabr A; Salem R; Lewandowski RJ J Vasc Interv Radiol; 2017 Nov; 28(11):1520-1526. PubMed ID: 28673658 [TBL] [Abstract][Full Text] [Related]
20. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Rhee TK; Lewandowski RJ; Liu DM; Mulcahy MF; Takahashi G; Hansen PD; Benson AB; Kennedy AS; Omary RA; Salem R Ann Surg; 2008 Jun; 247(6):1029-35. PubMed ID: 18520231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]